July 2nd, 2010

TMRC Co., Ltd.

A Phase II study of TM-411, for the treatment of HCC (Licensed to Zeria Pharmaceuticals) will be initiated.

TMRC had concluded on August 27, 2007 a license agreement with a Japanese company, Zeria Pharmaceutical co., Ltd., (located in Chuo-Ku, Tokyo, Sachiaki Ibe, President & CEO), to license out TM-411(Tamibarotene), to be developed as an anticancer drug for the treatment of hepatocellular carcinoma (HCC) in Japan, with co-development, exclusive manufacturing and marketing rights. Afterwards, Zeria has conducted the phase I portion of a phase I/II clinical study of the product, as development code Z-208.

TMRC today announced that the phase II portion of the study will be initiated with a recommended dose proposed by the safety and efficacy evaluation committee.

The primary objective of the study is to evaluate the safety and efficacy of TM-411 in the HCC patients whose standard therapy is no longer feasible.

TM-411has been confirmed by pre-clinical studies to inhibit the HCC cell growth and angiogenesis through binding to retinoic acid receptor (RAR-α) highly expressed in HCC and vascular endothelial cells. Based on these actions, TM-411 has been expected to be a safe molecular target therapy agent for the HCC patients.
The mortality rate of HCC in Japan is more than 80% and it is extremely high compared with its incidence and the third cause of cancer death.

TMRC and Zeria promote the co-development for HCC in Japan and Zeria will manufacture and distribute the product after obtaining an approval.

※Tamibarotene

Tamibarotene is a synthetic retinoid originally synthesized by the University of Tokyo, which was designed to improve chemical stability, safety and efficacy as compared with existing retinoid compounds, shows a strong differentiation induction activity.

TOKO Pharmaceutical Co. Ltd. had developed the product and obtained an approval for use in relapsed/refractory APL in April 11th, 2005 and marketed as “Amnolake® Tablet 2mg” in June, 2005.

TMRC has been developing the product for APL through our licensing partners in U.S./Europe (CytRx Corporation: U.S.A) and China (Lotus Co., Ltd.: Minato-ku, Tokyo).

- **TMRC Co., Ltd.**

Head office :	6-3, Nibancho, Chiyoda-ku, Tokyo 102-0084, JAPAN
Paid-in capital:	Yen 50 Mil.
Representative:	Hisao Ekimoto, Ph.D. (President &CEO)
Business activity:	Development,Licensing and Marketing of innovative anti-cancer Drugs
URL :	http://www.tmrc.co.jp/

- **Zeria Pharmaceutical Co., Ltd.**

Head office:	10-11, Nihonbashi, Kobuna-cho, Chuo-ku, Tokyo 103-8351, JAPAN
Paid-in capital:	¥6,593,398,500
Representative:	Sachiaki Ibe (President &CEO)
Business activity:	1) Manufacture, sales, import and export of pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals and reagents; 2) Manufacture, sales, import and export of cosmetics, health foods, alcoholic beverages, carbonated beverages, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, measuring equipment, analytical equipment; and 3) Activities related to the items described in 1) and 2)
URL :	http://www.zeria.co.jp/english/